FASN and metabolic dysfunction-associated steatotic liver disease: Furthermore, we identified that the FDA-approved FASN inhibitor orlistat could interrupt NAFLD-induced lipid metabolic reprogramming, thus inhibiting EGFR palmitoylation and decreasing its stability and PM localization to suppress CRC cell stemness and restrict liver metastasis in synergy with conventional chemotherapy.